Fred Aslan, Director, Chief Executive Officer, on September 08, 2026, sold 23,429 shares in Artiva Biotherapeutics (ARTV) for $255,746. Following the Form 4 filing with the SEC, Aslan has control over a total of 1,449,765 common shares of the company, with 1,449,765 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1817241/000119312526386431/xslF345X05/ownership.xml